Comparison of the efficacy of the multimodal serotonergic antidepressants trazodone and vortioxetine in the treatment of patients with endogenous depression: A meta-analysis of double-blind randomized placebo-controlled trials
https://doi.org/10.14412/2074-2711-2017-1-11-19
Abstract
Selective serotonergic antidepressants with a miltimodal mechanism of action are a new group of antidepressants, which includes trazodone and vortioxetine. Data on the efficacy of trazodone and vortioxetine in treating endogenous depression (major depressive disorder) appear to be rather uncertain now. There have been no direct comparative trials of the efficiency of therapy with trazodone and vortioxetine.
Objective: to compare the efficiency of therapy with trazodone and vortioxetine in treating patients with endogenous depression on the basis of statistical generalization of the results of studies of the efficacy of each antidepressant alone.
Material and methods. On the basis of the selection criteria, 7 double-blind, randomized, placebo-controlled trials of the efficiency of therapy with trazodone or vortioxetine in patients with endogenous depression were chosen from the PubMed database. The trials were divided into 2 groups according to the comparability of original samples of patients, methods for evaluating their state, and duration of follow-up. The efficiency of therapy with trazodone and that of vortioxetine were compared by determining the statistical significance of differences in the ratio of responders/nonresponders or remitters/nonremitters in Groups 1 and 2 separately.
Results. 1) Comparison of the values of 8-week therapy efficiency in Group 1: a) therapy with trazodone at an average dose of about 300 mg/day significantly more frequently results in the alleviation of depressive symptoms to the level of classifying patients into the category of responders than that with vortioxetine at an average dose of about 9 mg/day; b) therapy with trazodone at an average dose of about 300 mg/day significantly more often relieves depressive symptoms to the level of classifying patients into a category of remitters than that with vortioxetine at average dose of about 9 mg/day; c) therapy with trazodone at an average dose of about 300 mg/day and that with vortioxetine at an average dose of about 18.5 mg/day lead to the comparable reduction of depressive symptoms to the level of referring patients to a category of responders or remitters. 2) Comparison of the values of of 6-week treatment efficacy in Group 2: therapy with trazodone at an average dose of about 300 mg/day is statistically significantly less frequently accompanied by the attenuation of depressive symptoms to the level of assigning patients to a category of responders than that with vortioxetine at average dose of about 7.5 mg/day. The validity of the results of comparing the efficiency of therapy in Group 2 is constrained by incomplete comparability of the clinical and demographic characteristics of initial patient samples.
Conclusion. The findings suggest the higher efficacy of trazodone 300 mg/day versus vortioxetine 5–10 mg/day and the comparable efficacy of trazodone 300 mg/day and vortioxetine 15–20 mg/day in treating patients with endogenous depression.
About the Author
D. S. DanilovRussian Federation
S.S. Korsakov Clinic of Psychiatry, University Clinical Hospital Three
11, Rossolimo St., Build. 9, Moscow 119435
References
1. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015 Jan;145:43-57. doi: 10.1016/j.pharmthera.2014.07.001. Epub 2014 Jul 9.
2. Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs. 2014 Sep;28(9):855-74. doi: 10.1007/s40263-014-0195-x.
3. Шагиахметов ФШ, Анохин ПК, Шамакина ИЮ. Вортиоксетин: механизмы мультимодальности и клиническая эффективность. Социальная и клиническая психиатрия. 2016;26(4):84-96. [Shagiakhmetov FSh, Anokhin PK, Shamakina IYu. Vortioxetine: mechanisms of multimodality and clinical efficacy. Sotsial'naya i klinicheskaya psikhiatriya. 2016;26(4):84-96. (In Russ.)].
4. Мосолов СН. Клиническое применение современных антидепрессантов. Санкт-Петербург: МИА; 1995. 568 с. [Mosolov SN. Klinicheskoe primenenie sovremennykh antidepressantov [Clinical use of modern antidepressants]. Saint-Petersburg: MIA; 1995. 568 p.]
5. Шацберг АФ, Коул ДО, ДеБаттиста Ч. Руководство по клинической фармакологии. Москва: МЕДпресс-информ; 2013. 608 с. [Shatsberg AF, Koul DO, DeBattista Ch. Rukovodstvo po klinicheskoi farmakologii [Manual of clinical pharmacology]. Moscow: MEDpress-inform; 2013. 608 p.]
6. Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m- chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005 May;19(3):235-41.
7. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009 Oct; 14(10):536-46.
8. Frecska E. Trazodone – its multifunctional mechanism of action and clinical use (article in Hungarian). Neuropsychopharmacol Hung. 2010 Dec;12(4):477-82.
9. Patten SB. The comparative efficacy of trazodone and imipramine in the treatment of depression. CMAJ. 1992 Apr 1;146(7):1177-82.
10. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007 Oct;22(7):444-7. Epub 2007 Apr 5.
11. Каплан ГИ, Сэдок БД. Клиническая психиатрия. Т.2. Москва: Медицина; 1994. 528 с. [Kaplan GI, Sedok BD. Klinicheskaya psikhiatriya [Clinical psychiatry]. Vol. 2. Moscow: Meditsina; 1994. 528 p.]
12. Арана Дж, Розенбаум Дж. Фармакотерапия психических расстройств. Москва: Бином; 2004. 416 с. [Arana Dzh, Rozenbaum Dzh. Farmakoterapiya psikhicheskikh rasstroistv [Pharmacotherapy of mental disorders]. Moscow: Binom; 2004. 416 p.]
13. Pae CU, Wang SM, Han C, et al. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci. 2015 May;40(3):174-86.
14. Kelliny M, Croarkin PE, Moore KM, et al. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Ther Clin Risk Manag. 2015 Aug 12;11:1193-212. doi: 10.2147/TCRM.S55313. eCollection 2015.
15. Thase ME, Mahableshwarkar AR, Dragheim M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016 Jun;26(6):979-93. doi: 10.1016/j.euroneuro.2016.03.007. Epub 2016 Mar 25.
16. Sheehan DV, Croft HA, Gossen ER, et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebocontrolled study. Psychiatry (Edgmont). 2009 May;6(5):20-33.
17. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012 Jul;73(7):953-9. doi: 10.4088/JCP.11m07470.
18. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo- controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014 May;29(3):138-49. doi: 10.1097/YIC.0000000000000018.
19. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014 Oct;17(10):1557-67. doi: 10.1017/S1461145714000546. Epub 2014 Apr 30.
20. Jacobsen PL, Mahableshwarkar AR, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry. 2015 May;76(5):575-82. doi: 10.4088/JCP.14m09335.
21. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994 Apr;14(2):99-106.
22. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012 Jun;15(5): 589-600. doi: 10.1017/S1461145711001027. Epub 2011 Jul 18.
23. Oleptro™ (trazodone hydrochloride) extendedrelease tablets. P T. 2011 Feb;36(2):2-18.
24. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr. 2015 Apr;20(2):93-7. doi: 10.1017/S1092852915000139.
Review
For citations:
Danilov DS. Comparison of the efficacy of the multimodal serotonergic antidepressants trazodone and vortioxetine in the treatment of patients with endogenous depression: A meta-analysis of double-blind randomized placebo-controlled trials. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(1):11-19. (In Russ.) https://doi.org/10.14412/2074-2711-2017-1-11-19